German hype just that:
SAN FRANCISCO, Aug. 5 /PRNewswire/ -- The following is being issued by
BancBoston Robertson Stephens, a member of the National Association of
Securities Dealers, CRD number 41271:
BancBoston Robertson Stephens senior medical device and medical technology
analyst Wade H. King, M.D., reiterated his Buy rating on VISX, Inc.
(Nasdaq: VISX). VISX, headquartered in Santa Clara, Calif., is a leading
manufacturer of excimer laser systems used to perform laser vision correction
(LVC) procedures.
"We are reiterating our Buy rating on VISX. Over the last two days,
shares of VISX have declined 13 percent," said King. "We attribute this
weakness in part to sensationalized concerns regarding night vision problems
after LVC surgery, following a recent BBC article. Interestingly, the article
cited data from a German study of only 26 patients who underwent
photorefractive keratotomy (PRK) where an older-generation Summit laser was
used, not a VISX laser."
Doctors have performed approximately one million LVC cases in the U.S. to
date.
"In our view, most patients are generally ecstatic about their results,
with the incidence of adverse reactions following LVC surgery being remarkably
low," said King.
"We believe that there is no comparable growth and investment opportunity
in the medical device universe today," said King "We encourage investors to
view any weakness in share price as a buying opportunity and reiterate our
price target for shares of VISX to $125."
OK, Phil, PRK!!!! NOT A VISX. Like I said.
Put it to rest. |
